Profile data is unavailable for this security.
About the company
OptiBiotix Health Plc is a United Kingdom-based life sciences company. The Company is primarily engaged in identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry segment. Its technology platforms include OcptiBiome, OptiScreen and OptiBiotic. Its OptiBiome technology platform that screens identifies and/or develops microbiome modulators, which can be used in formulations to prevent, manage and a range of chronic lifestyle diseases. The OptiScreen pharmaceutical screening platform to identify microbial metabolic pathways that interact with human pathways to improve health. The OptiBiotic platform generates oligosaccharides and screens them for their ability to modulate specific microbial genera or species and their microbial end products (short chain fatty acids, such as acetate, propionate, butyrate) and physical properties (sweetness). Its products include SlimBiome, SweetBiotix, CholBiomeX3, SlimBiome Medical and WellBiome.
- Revenue in GBP (TTM)569.00k
- Net income in GBP-2.98m
- Incorporated2006
- Employees5.00
- LocationOptiBiotix Health PLCInnovation CentreInnovation Way, HeslingtonHESLINGTON Y010 5DGUnited KingdomGBR
- Phone+44 207 933 8780
- Websitehttp://www.optibiotix.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N4 Pharma PLC | 5.86k | -1.12m | 2.57m | 5.00 | -- | 2.05 | -- | 437.90 | -0.0042 | -0.0042 | 0.00002 | 0.0032 | 0.0041 | -- | 0.0421 | 1,172.00 | -79.19 | -57.05 | -83.28 | -61.13 | -- | -- | -19,152.56 | -309,312.80 | -- | -3,023.17 | 0.00 | -- | -- | -51.52 | -24.05 | -- | -- | -- |
| Fusion Antibodies PLC | 1.80m | -1.63m | 4.03m | 31.00 | -- | 3.78 | -- | 2.24 | -0.0214 | -0.0214 | 0.0225 | 0.0111 | 1.01 | 3.81 | 2.92 | 58,129.03 | -90.74 | -41.50 | -125.54 | -52.23 | 20.20 | 40.19 | -90.29 | -56.92 | 2.73 | -- | 0.0293 | -- | -60.84 | -12.24 | 14.25 | -- | -72.95 | -- |
| Genflow Biosciences PLC | 0.00 | -1.53m | 6.12m | 5.00 | -- | 7.13 | -- | -- | -0.0051 | -0.0051 | 0.00 | 0.0025 | 0.00 | -- | -- | 0.00 | -93.85 | -- | -118.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.97 | -- | -- | -- |
| ImmuPharma PLC | -69.96k | -2.46m | 6.54m | 5.00 | -- | 2.43 | -- | -- | -0.0065 | -0.0065 | -0.0002 | 0.0065 | -0.019 | -- | -- | -13,992.00 | -66.99 | -86.13 | -111.20 | -106.39 | -- | -- | -- | -8,634.98 | -- | -7.27 | 0.00 | -- | -- | -- | 23.26 | -- | -- | -- |
| LungLife AI Inc | 23.04k | -3.55m | 7.32m | 15.00 | -- | 0.3556 | -- | 317.62 | -0.1334 | -0.1334 | 0.0009 | 0.2473 | 0.0027 | -- | 2.90 | 1,536.09 | -42.18 | -- | -47.78 | -- | 100.00 | -- | -15,403.45 | -- | -- | -- | 0.0259 | -- | 91.67 | -- | 28.83 | -- | -- | -- |
| Cizzle Biotechnology Holdings PLC | 0.00 | -2.70m | 7.53m | 67.00 | -- | 9.49 | -- | -- | -0.0073 | -0.0073 | 0.00 | 0.002 | 0.00 | -- | -- | -- | -146.70 | -144.15 | -157.81 | -167.75 | -- | -- | -- | -- | -- | -0.45 | 0.00 | -- | -- | -- | -88.27 | -- | -- | -- |
| Synairgen plc | 0.00 | -6.92m | 9.38m | 36.00 | -- | 0.9751 | -- | -- | -0.0344 | -0.0344 | 0.00 | 0.0475 | 0.00 | -- | -- | 0.00 | -47.18 | -54.01 | -54.24 | -60.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.35 | -- | -26.64 | -- |
| IXICO PLC | 6.00m | -1.87m | 11.12m | 89.00 | -- | 0.578 | -- | 1.85 | -0.0386 | -0.0386 | 0.1241 | 0.2076 | 0.4725 | -- | 3.54 | 67,415.73 | -14.69 | 4.35 | -16.58 | 5.33 | 46.90 | 62.09 | -31.10 | 6.61 | -- | -- | 0.0312 | 0.00 | -22.89 | 4.32 | -214.15 | -- | 92.12 | -- |
| OptiBiotix Health PLC | 569.00k | -2.98m | 12.00m | 5.00 | -- | 1.63 | -- | 21.09 | -0.0317 | -0.0317 | 0.0061 | 0.0752 | 0.0634 | 1.35 | 1.07 | 113,800.00 | -33.25 | 16.82 | -34.85 | 17.52 | 47.98 | 53.03 | -524.43 | 183.49 | 5.36 | -2.03 | 0.00 | 100.14 | 40.92 | 4.60 | -178.82 | -- | -- | -- |
| Incanthera PLC | 0.00 | -1.55m | 16.37m | 7.00 | -- | -- | -- | -- | -0.0189 | -0.0189 | 0.00 | -0.0061 | 0.00 | -- | -- | 0.00 | -852.34 | -115.31 | -- | -153.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -12.76 | -- | -- | -- |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -5.18m | 21.38m | 17.00 | -- | 6.68 | -- | -- | -0.0042 | -0.0042 | 0.00 | 0.0023 | 0.00 | -- | -- | 0.00 | -77.79 | -82.19 | -85.95 | -95.97 | -- | -- | -- | -- | -- | -19.94 | 0.4794 | -- | -- | -- | -68.14 | -- | 36.68 | -- |
| Shield Therapeutics PLC | 20.88m | -36.17m | 23.07m | 73.00 | -- | 42.64 | -- | 1.10 | -0.0477 | -0.0477 | 0.0274 | 0.0007 | 0.4723 | 4.06 | 1.69 | 286,068.50 | -81.80 | -56.68 | -136.41 | -67.44 | 34.65 | 52.20 | -173.18 | -365.89 | 0.8968 | -15.29 | 0.9736 | -- | 137.95 | 1.95 | 33.13 | -- | -2.50 | -- |
| Arecor Therapeutics PLC | 4.90m | -8.67m | 28.88m | 50.00 | -- | 4.61 | -- | 5.90 | -0.283 | -0.283 | 0.16 | 0.1658 | 0.3213 | -- | 1.67 | 97,980.00 | -56.84 | -- | -89.06 | -- | -- | -- | -176.89 | -- | 1.27 | -- | 0.0523 | -- | 90.30 | -- | 7.62 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to OptiBiotix Health PLC's reporting currency: UK Pound GBX
23.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| KW Investment Management Ltd.as of 01 Jun 2024 | 10.35m | 10.57% |
| Hargreaves Lansdown Asset Management Ltd.as of 01 Jun 2024 | 4.60m | 4.69% |
| IG Markets Ltd.as of 01 Jun 2024 | 2.22m | 2.27% |
| Jarvis Investment Management Ltd.as of 01 Jun 2024 | 1.68m | 1.71% |
| HSBC Global Asset Management (UK) Ltd.as of 01 Jun 2024 | 1.49m | 1.52% |
| Rathbones Investment Management Ltd.as of 01 Jun 2024 | 1.37m | 1.39% |
| HSBC Bank Plc (Market-Maker)as of 01 Jun 2024 | 564.00k | 0.58% |
| iDealing.com Ltd.as of 01 Jun 2024 | 351.00k | 0.36% |
| Winterflood Securities Ltd (Market-Maker)as of 01 Jun 2024 | 273.00k | 0.28% |
| Evelyn Partners Investment Management Services Ltd.as of 01 Jun 2024 | 163.00k | 0.17% |
More ▼
Data from 31 Dec 2023 - 05 Nov 2024Source: FactSet Research Systems Inc.
